Table 1.

Comparison of the clinical and laboratory parameters between the study cohort and the historical cohort

Characteristic	Bortezomib cohort (n = 22) N (%)Mean ± SD/ Median(IQR)	Historical cohort (n = 29) N (%) Mean ± SD/ Median(IQR)	P Value
Upfront therapy
ATO based	21 (95.5)	24 (82.8)	0.218
ATRA based	1 (4.5)	5 (17.2)
Use of anthracycline in upfront therapy	10 (45.5)	13 (44.8)	0.964
Time from initial diagnosis to relapse (in months)	23.1 (15.6 to 43.8)	20.6 (14.3 to 33.2)	0.481
Age (in years)	26.5 (17.5 to 41.5)	26 (8.0 to 43.0)	0.402
Gender: Male	14 (63.64)	22 (75.9)	0.343
Patients with promyelocytes and blasts in peripheral blood	6 (27.3)	21 (75.0)	0.001
Hemoglobin (g/dL)	12.7 (10.3 to 13.7)	11.6 (10.2 to 13.6)	0.430
White blood cell count ( in 109/L)	2.65 (1.63 to 6.59)	3.45 (1.43 to 13.13)	0.417
Platelet count ( in 109/L)	112 (37.8 to 154.3)	49 (19.5 to 76.8)	0.010
Serum creatinine (in mg/dL)	0.75 (0.65 to 0.85)	0.82 (0.64 to 1.00)	0.183
Prothrombin time (in s)	11.8 (11.15 to 13.75)	13.9 (13.0 to 15.5)	0.002
Activated partial thromboplastin time (in s)	31.7 (28.5 to 32.7)	30.0 (26.1 to 34.8)	0.441
Plasma fibrinogen (in mg%)	200.7 (102.5 to 249.5)	117.45 (82.4 to 158.5)	0.076
Percentage of bone marrow blasts and promyelocytes	64.0 (49.0 to 77.5)	75.5 (67.5 to 90.5)	0.059
Major bleeding at presentation	2 (9.1)	2 (7.4)	1.000
Major thrombosis at presentation	0 (0)	3 (11.5)	0.242
Transfusions during induction
Packed red cell concentrates	1 (0 to 4)	1.5 ( 0 to 2.3)	0.691
Fresh frozen plasma	0 (0 to 5)	4 (1.5 to 16.3)	0.015
Cryoprecipitate	0 (0 to 8.5)	5.5 (0 to 9.0)	0.332
Platelet rich concentrate	10 (0 to 29.3)	11 (4.3 to 26.5)	0.690
Patients with molecular remission post induction	19 (90.5)	16 (69.6)	0.137
Duration of follow‐up (in months)	48 (28 to 56.3)	69 (7 to 113.5)	0.361